- Active not recruitingPHASE3
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
This study is testing a new drug called ianalumab for people with lupus (SLE). It aims to see if ianalumab, given alongside usual lupus treatments, is safe and helps improve symptoms. It's for adults and some teenagers with active lupus.
For: Systemic Lupus ErythematosusUnited States · Argentina · Australia - Active not recruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
For: Diffuse Cutaneous Systemic SclerosisUnited States · Argentina · Austria - Active not recruitingPHASE2
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
This study is looking at a new medicine called ianalumab for adults with a blood condition called ITP. We want to see how well it works, if it's safe, and how people tolerate it, especially if other treatments haven't helped enough.
For: Primary Immune Thrombocytopenia (ITP)United States · Argentina · Australia - Active not recruitingPHASE3
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
This study is for adults with a blood condition called ITP who haven't improved with steroid treatment. It's testing a new drug called ianalumab, given with another drug called eltrombopag, to see if it can help keep blood platelet levels stable and safe for longer.
For: Primary Immune ThrombocytopeniaUnited States · Argentina · Austria - RecruitingPHASE3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
This study looks at the long-term safety of a new medicine, ianalumab, for people with lupus. It's for those who have already been in an earlier ianalumab study and continues to check how safe and well the medicine is tolerated over time.
For: Systemic Lupus ErythematosusUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
This study is looking at a new medicine called ianalumab for adults with a blood condition called ITP. We want to see if ianalumab, when given with standard treatment (steroids), can help keep platelet counts up. Half the participants will get ianalumab, and half will get a dummy medicine.
For: Primary Immune Thrombocytopenia (ITP)United States · Argentina · Australia - Active not recruitingPHASE3
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
This study looks at a new medicine, ianalumab, for people with warm autoimmune hemolytic anemia (wAIHA) who haven't responded to previous treatments. It aims to see if ianalumab can increase healthy red blood cells and if it is safe.
For: Warm Autoimmune Hemolytic Anemia (wAIHA)United States · Argentina · Australia - RecruitingPHASE2
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
This study looks at giving a second course of ianalumab to adults with certain blood conditions (ITP or wAIHA) if their first treatment worked but then stopped or wasn't enough. It's to see if a second round is safe and helps them again.
For: Primary Immune Thrombocytopenia · Warm Autoimmune Hemolytic AnemiaArgentina · Belgium · China